爱泼斯坦-巴尔病毒DNA水平作为鼻咽癌的一种新的预后因素：一项荟萃分析。
Epstein-Barr virus DNA level as a novel prognostic factor in nasopharyngeal carcinoma: A meta-analysis.
作者信息
Zhang Jing, Shu Chi, Song Yanlin, Li Qingfang, Huang Jingwen, Ma Xuelei
机构信息
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy Department of Neurosurgery Department of Vascular Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China.
出版信息
Medicine (Baltimore). 2016 Oct;95(40):e5130. doi: 10.1097/MD.0000000000005130.
BACKGROUND
The plasma Epstein-Barr virus (EBV) DNA level in patients with nasopharyngeal carcinoma (NPC) performs as an appealing prognostic factor, but conclusions of its prognostic values from previous studies are inconsistent. In this study, we performed a comprehensive meta-analysis to evaluate the prognostic value of EBV DNA level in patients with NPC.
METHODS
Published studies were searched in PubMed. The baseline characteristics of patients, overall survival (OS), and other survival outcomes were extracted. Pooled hazard ratio (HR), 95% confidence interval (CI), and P value were calculated to estimate the prognostic value of EBV DNA level. Each cut-off value mentioned in the studies was obtained. Kaplan-Meier curves were used to extract data, and graphical survival plots were extracted for calculating HR when the study did not describe the information directly.
RESULTS
This meta-analysis pooled 23 eligible studies including 10,732 patients with NPC. The pooled HR (95% CI) of pretreatment plasma EBV DNA level (pre-DNA) for OS was 2.78 (2.19, 3.55), and the HR (95% CI) of posttreatment plasma EBV DNA level (post-DNA) for OS was 5.43 (2.72, 10.82), suggesting that EBV DNA level was significantly correlated to the outcomes of patients with NPC.
CONCLUSION
High expression levels of EBV DNA predicts poor prognosis in NPC.
背景
鼻咽癌（NPC）患者血浆中爱泼斯坦-巴尔病毒（EBV）DNA水平是一个有吸引力的预后因素，但以往研究对其预后价值的结论并不一致。在本研究中，我们进行了一项全面的荟萃分析，以评估EBV DNA水平在NPC患者中的预后价值。
方法
在PubMed中检索已发表的研究。提取患者的基线特征、总生存期（OS）和其他生存结局。计算合并风险比（HR）、95%置信区间（CI）和P值，以评估EBV DNA水平的预后价值。获取研究中提到的每个临界值。当研究未直接描述相关信息时，使用Kaplan-Meier曲线提取数据，并提取生存曲线图以计算HR。
结果
该荟萃分析纳入了23项符合条件的研究，共10732例NPC患者。治疗前血浆EBV DNA水平（pre-DNA）对OS的合并HR（95%CI）为2.78（2.19，3.55），治疗后血浆EBV DNA水平（post-DNA）对OS的HR（95%CI）为5.43（2.72，10.82），这表明EBV DNA水平与NPC患者的预后显著相关。
结论
EBV DNA高表达预示NPC患者预后不良。
Zotero 插件